Androgen receptor-negative (AR-) prostate tumours are observed in 11-24% of prostate cancer patients. To date, no treatments have been clinically approved for AR- prostate cancers. Histone deacetylases (HDACs) are overexpressed in late-stage prostate cancers and in AR- prostate cancer cell lines (PC3 and DU145). However, HDAC inhibitors, including suberanlihohydroxamic acid (SAHA), showed toxicity and lack of efficacy in clinical trials for prostate cancer. Novel HDAC inhibitors, N1-hydroxy-N8-(4-(pyridine-2-carbothioamido)phenyl)octanediamide) (Jazz90) and [chlorido(η5-pentamethylcyclopentadienyl)(N1-hydroxy-N8-(4-(pyridine-2-carbothioamido-κ2N,S)phenyl)octanediamide)rhodium(III)] chloride (Jazz167), were synthesised based on SAHA with the...
The anti-epileptic drug valproic acid is also under trial as an anti-cancer agent due to its histone...
The anti-epileptic drug valproic acid is also under trial as an anti-cancer agent due to its histone...
The anti-epileptic drug valproic acid is also under trial as an anti-cancer agent due to its histone...
Metastatic castration-resistant prostate cancer (CRPC) has a five-year survival rate of 28%. As hist...
Histone deacetylase inhibitors (HDACIs) are showing promise as therapeutic agents for hematological ...
<p>The androgen receptor (AR) signaling axis is a well-established therapeutic target in prostate ca...
<div><p>Histone deacetylase inhibitors (HDACi) represent a promising class of epigenetic agents with...
Historically, androgen-deprivation therapy has been the cornerstone for treatment of metastatic pros...
Diverse cellular processes relevant to cancer progression are regulated by the acetylation status of...
Histone deacetylase inhibitors (HDACi) represent a promising class of epigenetic agents with antican...
[[abstract]]Purpose: To assess the antitumor effects of a novel phenylbutyrate-derived histone deace...
[[abstract]]Purpose: To assess the antitumor effects of a novel phenylbutyrate-derived histone deace...
© 2007 American Association for Cancer ResearchGrowth of prostate cancer cells is initially dependen...
We identified the molecular target by histone deacetylase (HDAC) inhibitors for exploring their pote...
We identified the molecular target by histone deacetylase (HDAC) inhibitors for exploring their pote...
The anti-epileptic drug valproic acid is also under trial as an anti-cancer agent due to its histone...
The anti-epileptic drug valproic acid is also under trial as an anti-cancer agent due to its histone...
The anti-epileptic drug valproic acid is also under trial as an anti-cancer agent due to its histone...
Metastatic castration-resistant prostate cancer (CRPC) has a five-year survival rate of 28%. As hist...
Histone deacetylase inhibitors (HDACIs) are showing promise as therapeutic agents for hematological ...
<p>The androgen receptor (AR) signaling axis is a well-established therapeutic target in prostate ca...
<div><p>Histone deacetylase inhibitors (HDACi) represent a promising class of epigenetic agents with...
Historically, androgen-deprivation therapy has been the cornerstone for treatment of metastatic pros...
Diverse cellular processes relevant to cancer progression are regulated by the acetylation status of...
Histone deacetylase inhibitors (HDACi) represent a promising class of epigenetic agents with antican...
[[abstract]]Purpose: To assess the antitumor effects of a novel phenylbutyrate-derived histone deace...
[[abstract]]Purpose: To assess the antitumor effects of a novel phenylbutyrate-derived histone deace...
© 2007 American Association for Cancer ResearchGrowth of prostate cancer cells is initially dependen...
We identified the molecular target by histone deacetylase (HDAC) inhibitors for exploring their pote...
We identified the molecular target by histone deacetylase (HDAC) inhibitors for exploring their pote...
The anti-epileptic drug valproic acid is also under trial as an anti-cancer agent due to its histone...
The anti-epileptic drug valproic acid is also under trial as an anti-cancer agent due to its histone...
The anti-epileptic drug valproic acid is also under trial as an anti-cancer agent due to its histone...